BDRX (Biodexa Pharmaceuticals) 3-Year RORE % : -27.28% (As of Dec. 2025)


BDRX Biodexa Pharmaceuticals PLC BDRX
45 GF Score
Price $2.60
GF Value $2.33
Valuation Modestly Overvalued
View Full Analysis

What is Biodexa Pharmaceuticals 3-Year RORE %?

Biodexa Pharmaceuticals BDRX -3.35% 45 3-Year RORE % is -27.28 as of Dec. 2025. GuruFocus rates BDRX with a GF Score™ of 45/100 and a GF Value™ of $2.33 (Modestly Overvalued). Among 1,287 Biotechnology companies, Biodexa Pharmaceuticals ranks worse than 66.43% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Biodexa Pharmaceuticals's 3-Year RORE % for the quarter that ended in Dec. 2025 was -27.28%.

The industry rank for Biodexa Pharmaceuticals's 3-Year RORE % or its related term are showing as below:

BDRX's 3-Year RORE % is ranked worse than
66.43% of 1287 companies
in the Biotechnology industry
Industry Median: -11.53 vs BDRX: -27.28

Biodexa Pharmaceuticals  (NAS:BDRX) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Biodexa Pharmaceuticals 3-Year RORE % Related Terms


Biodexa Pharmaceuticals 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Biodexa Pharmaceuticals's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodexa Pharmaceuticals 3-Year RORE % Chart

Biodexa Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.67 -65.65 -49.75 -99.76 -27.28

Biodexa Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.75 -54.06 -99.76 -103.66 -27.28

BDRX vs ADTX, AAGH, PKTX: 3-Year RORE % Comparison

For the Biotechnology subindustry, Biodexa Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biodexa Pharmaceuticals 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biodexa Pharmaceuticals's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Biodexa Pharmaceuticals's 3-Year RORE % falls into.


BDRX
45GF Score
Biodexa Pharmaceuticals PLC BDRX
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodexa Pharmaceuticals 3-Year RORE % Calculation

Biodexa Pharmaceuticals's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -143.326--575.374 )/( -1583.719-0 )
=432.048/-1583.719
=-27.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -27.28 mean?
Biodexa Pharmaceuticals (BDRX) has a 3-Year RORE % of -27.28 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Biodexa Pharmaceuticals and its competitors. According to the industry distribution chart, Biodexa Pharmaceuticals ranks #855 out of 1287 companies in the Biotechnology industry, placing it in the top 66.4%.
Is Biodexa Pharmaceuticals' 3-Year RORE % too high?
Biodexa Pharmaceuticals' current 3-Year RORE % is -27.28. Based on the distribution chart, Biodexa Pharmaceuticals ranks #855 out of 1287 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Biodexa Pharmaceuticals has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biodexa Pharmaceuticals' 3-Year RORE % compare to ADTX and AAGH?
According to the Biotechnology industry distribution chart, Biodexa Pharmaceuticals ranks #855 out of 1287 companies for 3-Year RORE %. This places Biodexa Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Biodexa Pharmaceuticals and its competitors. Biodexa Pharmaceuticals's current 3-Year RORE % is -27.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodexa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Biodexa Pharmaceuticals (BDRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.33, compared to a current price of $2.60 — trading 11.6% above its estimated fair value. The current 3-Year RORE % is -27.28. Biodexa Pharmaceuticals' overall GF Score™ is 45/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Biodexa Pharmaceuticals (BDRX), the current 3-Year RORE % is -27.28 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodexa Pharmaceuticals (BDRX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodexa Pharmaceuticals stock appears to be overvalued. The current stock price of $2.60 is trading 11.6% above its estimated GF Value™ of $2.33. GuruFocus considers Biodexa Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for BDRX:

  • 3-Year RORE %: -27.28
  • GF Value™: $2.33 vs. price of $2.60 (11.6% above fair value)
  • GF Score™: 45/100

No single metric tells the full story. See the BDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biodexa Pharmaceuticals Business Description

Address 1 Caspian Point, Caspian Way, Cardiff, GBR, CF10 4DQ
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
45GF Score

Get the complete analysis for BDRX

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.60
Price
$2.33
GF Value